Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03287817
Previous Study | Return to List | Next Study

CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03287817
Recruitment Status : Recruiting
First Posted : September 19, 2017
Last Update Posted : October 18, 2019
Sponsor:
Information provided by (Responsible Party):
Autolus Limited

Brief Summary:
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 followed by limited duration of anti-PD1 antibody in patients with DLBCL

Condition or disease Intervention/treatment Phase
Diffuse Large B Cell Lymphoma Relapsed Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma DLBCL Biological: AUTO3 Phase 1 Phase 2

Detailed Description:
The study will consist of 2 phases, a Phase I or dose escalation phase and a Phase II or expansion phase. Patients with relapsed or refractory DLBCL will be enrolled in both phases of the study. Eligible patients will undergo leukapheresis in order to harvest T cells, which is the starting material for the manufacture of the autologous CAR T product AUTO3 which is a CD19 and CD22 dual targeting CAR T cell product. Following pre-conditioning by a chemotherapeutic regimen, the patient will receive AUTO 3 intravenously as a single dose and in addition a limited duration of treatment with an anti-PD1 antibody (either as part of the pre-conditioning regimen or consolidation). Patients will then enter a 24-month follow-up period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 146 participants
Intervention Model: Single Group Assignment
Intervention Model Description: A dose escalation phase (Phase 1) followed by a dose expansion phase (Phase 2; to further assess the recommended Phase II dose [RP2D]).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti PD1 Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Actual Study Start Date : September 5, 2017
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: AUTO3
Patient with relapsed or refractory DLBCL
Biological: AUTO3
Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells followed by limited duration of anti-PD1 antibody (pembrolizumab).




Primary Outcome Measures :
  1. Phase I - Safety (incidence of Grade 3-5 toxicities) and confirmation of phase II dose and schedule. [ Time Frame: Within 75 days of AUTO3 infusion. ]
  2. Phase II - Overall response rate as per Lugano criteria [ Time Frame: Up to 2 years ]

Secondary Outcome Measures :
  1. Feasibility of generating AUTO3: number of patients' cells successfully manufactured as a proportion of the number of patients undergoing leukapheresis. [ Time Frame: Up to 8 weeks post leukapheresis. ]
  2. Complete response rate, as per Lugano criteria. [ Time Frame: Up to 2 years ]
  3. Duration of response (DOR). [ Time Frame: Up to 2 years ]
  4. Progression-free survival (PFS). [ Time Frame: Up to 2 years ]
  5. Overall survival (OS). [ Time Frame: Up to 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, aged ≥18 years.
  2. Willing and able to give written, informed consent.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1.
  4. Histologically confirmed DLBCL and large B cell lymphoma (at last relapse) subsets, including:

    Phase I and Phase II Cohort 1:

    1. DLBCL, not otherwise specified (NOS), per World Health Organisation classification and DLBCL with MYC and BCL2 and/or BCL6 rearrangements (double/triple hit).
    2. Transformed DLBCL from FL.
    3. High-grade B cell lymphoma with MYC expression (excluding Burkitt's lymphoma)

      Phase I and Phase II Cohort 2:

    4. Transformed DLBCL from other indolent lymphomas (excluding Richter's transformation).
    5. Primary mediastinal large B cell lymphoma.
  5. Chemotherapy-refractory disease, defined as one or more of the following:

    1. Stable disease (≤12 months) or progressive disease as best response to most recent chemotherapy containing regimen. Refractory disease after frontline chemo-immunotherapy is allowed.
    2. Disease progression or recurrence in ≤12 months of prior autologous haematopoietic stem cells transplantation (ASCT).

    OR

  6. Relapse after ≥two lines of therapy or after ASCT. At a minimum:

    1. Patients must have received rituximab or another anti-CD20 monoclonal antibody (unless Investigator determines that tumour is CD20-negative) and an anthracycline-containing chemotherapy regimen.
    2. Patients must have either failed ASCT, or be ineligible for or not consenting to ASCT.
    3. Patients with transformed DLBCL must have received at least one line of therapy after transformation to DLBCL.
  7. PET-positive disease per Lugano classification.
  8. For females of childbearing potential, a negative serum or urine pregnancy test must be documented at screening, prior to pre-conditioning and confirmed before receiving the first dose of study treatment.

    For females who are not postmenopausal or surgically sterile, highly effective methods of contraception must be used during the treatment period and for at least 12 months after the last dose of study treatment.

  9. For males, it must be agreed that that two acceptable methods of contraception are used.
  10. Adequate renal, hepatic, pulmonary, and cardiac function defined as:

    1. Creatinine clearance ≥40 cc/min.
    2. Serum alanine aminotransferase / aspartate aminotransferase ≤2.5 x ULN.
    3. Total bilirubin ≤1.5 x ULN, except in subjects with Gilbert's syndrome.
    4. LVEF ≥50% (by ECHO or MUGA) unless the institutional lower limit of normal is lower.
    5. Baseline oxygen saturation >92% on room air and ≤Grade 1 dyspnoea.
  11. Patient has adequate BM function without requiring ongoing blood product or granulocyte-colony stimulating factor support and meets the following criteria:

    1. Absolute neutrophil count ≥1.0 × 109/L.
    2. Absolute lymphocyte count ≥0.3 × 109/L (at enrolment and prior to leukapheresis).
    3. Haemoglobin ≥80 g/L.
    4. Platelets ≥75 × 109/L
  12. No contra-indications for leukapheresis.

Exclusion Criteria:

  1. Prior allogeneic haematopoietic stem cell transplant.
  2. Females who are pregnant or lactating.
  3. History or presence of clinically relevant CNS pathology such as epilepsy, paresis, aphasia, stroke within prior 3 months, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, uncontrolled mental illness, or psychosis.
  4. Patients with active CNS involvement by malignancy. Patients with history of CNS involvement with malignancy may be eligible if CNS disease has been effectively treated and provided treatment was at least 4 weeks prior to enrolment (at least 8 weeks prior to AUTO3 infusion).
  5. Clinically significant, uncontrolled heart disease or a recent (within 12 months) cardiac event.

    1. Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded).
    2. Evidence of pericardial effusion
  6. Patients with a history (within 3 months) or evidence of deep vein thrombosis or pulmonary embolism requiring ongoing therapeutic anticoagulation at the time of pre-conditioning.
  7. Patients with active gastrointestinal bleeding.
  8. Patients with any major surgical intervention in the last 3 months.
  9. Active bacterial, viral or fungal infection requiring systemic treatment. Active or latent hepatitis B infection or hepatitis C infection. Testing positive for human immunodeficiency virus, human T cell lymphotropic virus (HTLV1 and 2) or syphilis.
  10. History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 24 months.
  11. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the CNS.
  12. Evidence of active pneumonitis on chest computed tomography (CT) scan at screening or history of drug-induced pneumonitis, idiopathic pulmonary fibrosis, organising pneumonia, or idiopathic pneumonitis.
  13. History of other malignant neoplasms unless disease free for at least 24 months (carcinoma in situ, non-melanoma skin cancer, breast or prostate cancer on hormonal therapy allowed).
  14. Prior treatment with PD1, PD-L1, or cytotoxic T lymphocyte-associated protein-4-targeted therapy, or tumour necrosis factor (TNF) receptor superfamily agonists.
  15. Prior treatment with investigational or approved gene therapy or cell therapy products until a dose level has treated at least three patients and has been declared safe.
  16. Prior CD19 or CD22 targeted therapy.
  17. The following medications are excluded:

    1. Steroids: Therapeutic doses of corticosteroids within 7 days of leukapheresis or 72 hours prior to AUTO3 administration. However, physiological replacement, topical, and inhaled steroids are permitted.
    2. Immunosuppression: Immunosuppressive medication must be stopped ≥2 weeks prior to leukapheresis or AUTO3 infusion.
    3. Cytotoxic chemotherapies within 2 weeks of AUTO3 infusion and 1 week prior to leukapheresis (2 weeks for lymphodepleting chemotherapy).
    4. Antibody therapy use including anti-CD20 therapy within 2 weeks prior to AUTO3 infusion, or 5 half-lives of the respective antibody, whichever is shorter.
    5. Granulocyte-colony stimulating factor less than 10 days prior to leukapheresis.
    6. Live vaccine ≤4 weeks prior to enrolment.
    7. Prophylactic intrathecal therapy: Methotrexate within 4 weeks and other intrathecal chemotherapy (e.g. Ara-C) within 2 weeks prior to starting pre-conditioning chemotherapy.
  18. Prior limited radiation therapy within 4 weeks of AUTO3 infusion or within 24 weeks for definitive radiation to chest.
  19. Research participants receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy.
  20. Known allergy to albumin, dimethyl sulphoxide (DMSO), cyclophosphamide or fludarabine, pembrolizumab or tocilizumab.
  21. Any contraindications to receive anti-PD1 antibody pembrolizumab will be excluded from cohorts requiring administration of pembrolizumab.
  22. Patients, who in the opinion of the Investigator, may not be able to understand or comply with the safety monitoring requirements of the study.
  23. Any other condition that in the Investigator's opinion would make the patient unsuitable for the clinical trial.

For AUTO3 Infusion: Patients meeting any of the following exclusion criteria must not be treated with AUTO3 or have treatment delayed until they no longer meet these criteria:

  1. Severe intercurrent infection.
  2. Requirement for supplementary oxygen or active pulmonary infiltrates.
  3. Clinical deterioration of organ function (renal and hepatic) exceeding the criteria set at study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03287817


Contacts
Layout table for location contacts
Contact: Autolus Limited +44 (0)203 911 4385 clinicaltrials@autolus.com

Locations
Layout table for location information
United States, Colorado
Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center/Sarah Cannon Research Institute Recruiting
Denver, Colorado, United States, 80218
Principal Investigator: Dr Peter McSweeney         
United States, Tennessee
TriStar Centennial Medical Center /Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Principal Investigator: Dr Carlos Bachier         
United States, Texas
St David's South Austin Medical Center /Sarah Cannon Research Institute Recruiting
Austin, Texas, United States, 78704
Principal Investigator: Dr Aravind Ramakrishnan         
United Kingdom
University College London Hospitals NHS Foundation Trust Recruiting
London, United Kingdom
Principal Investigator: Dr Kirit Ardeshna         
Manchester University NHS Foundation Trust Recruiting
Manchester, United Kingdom
Principal Investigator: Dr Nuria Martinez-Cibrian         
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust Recruiting
Newcastle upon Tyne, United Kingdom
Principal Investigator: Dr Wendy Osborne         
Sponsors and Collaborators
Autolus Limited

Layout table for additonal information
Responsible Party: Autolus Limited
ClinicalTrials.gov Identifier: NCT03287817     History of Changes
Other Study ID Numbers: AUTO3-DB1
2016-004682-11 ( EudraCT Number )
First Posted: September 19, 2017    Key Record Dates
Last Update Posted: October 18, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Autolus Limited:
Diffuse Large B Cell Lymphoma
Relapsed Diffuse Large B Cell Lymphoma
Refractory Diffuse Large B Cell Lymphoma
AUTO3
PD-1
Anti PD-1 antibody
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antibodies
Immunologic Factors
Physiological Effects of Drugs